• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us

Scientific Publications

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • Posters
  • Presentations
  • Publications
  • White Papers

03

Nov
2023

SITC 2023: A miRNA-based shRNA platform for the easy, safe,and effective generation of allogeneic CAR T-cells

Read More

03

Nov
2023

SITC 2023: Improvement of CAR T-cell performance by simultaneous downregulation of multiple co-inhibitory receptors

Read More

03

Nov
2023

SITC 2023: Proof-of-concept of a non-gene editing technology using shRNA down-regulation to engineer allogeneic CAR T-cells

Read More

03

Nov
2023

SITC 2023: NKG2D-based multispecific CAR T-cells to overcome antigen escape andimprove anti-tumor efficacy

Read More

03

Nov
2023

SITC 2023: Differential effects of target ligands and receptor architecture upon NKG2D-based CAR T-cell activation

Read More

20

Sep
2023

Efficient shRNA-based knockdown of multiple target genes for cell therapy using a chimeric miRNA cluster platform – Mol Ther Nucleic Acids 34:102038

Read More

12

Sep
2023

ICLE: Beyond CRISPR: non-gene editing, multiplex gene expression tuning for cell-based immunotherapy

Read More

12

Sep
2023

ICLE: Dual-targeting CD19 and NKG2D ligands CAR T-cells are effective against CD19 positive and CD19 negative B cell malignancies

Read More

30

Aug
2023

CAR-TCR Summit: Efficient shRNA-based knock-down of multiple target genes for cell therapy using a chimeric miRNA cluster platform

Read More

20

Feb
2023

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial – Lancet Haematol. 10(3):e191-e202

Read More

05

Oct
2022

Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non–Gene-edited Allogeneic CAR T-Cell Therapy – J Immunother. 45(3):150-161

Read More

25

Jan
2022

ASCO GI: KEYNOTE-B79 Phase 1b trial to evaluate the allogeneic CAR T-cells CYAD-101 and pembrolizumab in refractory metastatic colorectal cancer patients

Read More

13

Dec
2021

ASH: Data from CYAD-02 CYCLE 1 Phase 1 study and CYAD-211 IMMUNICY-1 Phase 1 study

Read More

13

Dec
2021

ASH: IMMUNICY-1: Targeting BCMA with CYAD-211 to Establish Proof Of Concept of An shRNA-based Allogeneic CAR T-cell Therapy Platform

Read More

12

Nov
2021

SITC: Armoring NKG2D-based CAR T cells with IL-18 improves in vitro and in vivo anti-tumor activity

Read More

12

Nov
2021

SITC: Evolving Multiplexed shRNA to generate tailored CAR T cell therapy

Read More

12

Nov
2021

SITC: A Phase 1b KEYNOTE-B79 trial evaluating non-gene edited allogeneic CAR T-cells, CYAD-101, post FOLFOX preconditioning, followed by pembrolizumab, in refractory metastatic colorectal cancer patients

Read More

11

Jun
2021

EHA: Objective response at low dose in the first-in-human IMMUNICY-1 trial evaluating non-gene edited allogeneic CYAD-211 anti-BCMA CAR T product in relapsed or refractory multiple myeloma

Read More

11

Jun
2021

EHA: Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in r/r MM

Read More

15

Jan
2021

ASCO GI: Updated Data from the alloSHRINK Phase 1 First-in-Human Study Evaluating CYAD-101, an Innovative Non-Gene-Edited Allogeneic CAR-T, in Metastatic Colorectal Cancer

Read More

24

Dec
2020

Whitepaper – Hairpins and Scissors – Delivering a Non-Gene Edited Allogeneic CAR T Cell Therapy for the Masses

Read More

05

Dec
2020

ASH: Results from the Phase I Clinical Studies Evaluating CYAD-01, a first-generation NKG2D CAR T-cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Read More

05

Dec
2020

ASH: Clinical Development of a Non-Gene-Edited Allogeneic BCMA-Targeting CAR T-cell Product in Relapsed or Refractory Multiple Myeloma

Read More

05

Dec
2020

ASH: First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating CYAD-02, an Optimized Non-Gene-Edited Engineered NKG2D CAR T-cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Read More

29

May
2020

ASCO: Single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T-cells

Read More

29

May
2020

ASCO: CYAD-101, an innovative non-gene edited allogeneic CAR-T for solid tumor cancer therapy

Read More

10

Jan
2020

The integrated stress response promotes B7H6 expression – J Mol Med 98(1): 135–148

Read More

09

Dec
2019

ASH: Results from the completed dose escalation of the hematological arm of the phase I THINK study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients

Read More

09

Dec
2019

ASH: Interim results from the phase I DEPLETHINK trial evaluating the infusion of a NKG2D CAR T-cell therapy post a non-myeloablative conditioning in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome patients

Read More

09

Dec
2019

ASH: Next generation NKG2D-based CAR-T cells (CYAD-02): Co-expression of a single shRNA targeting MICA and MICB improves cell persistence and anti-tumor efficacy in vivo

Read More

09

Dec
2019

Whitepaper – Development of the Next Generation NKG2D CAR T-cell Manufacturing Process

Read More

09

Nov
2019

SITC: Results from the completed dose-escalation of the ALLOSHRINK phase I study evaluating the allogeneic NKG2D-based CAR T-cell therapy CYAD-101 in metastatic colorectal cancer patients

Read More

09

Nov
2019

SITC: Results from the completed dose-escalation phase I SHRINK study evaluating the autologous NKG2D-based CAR T-cell therapy CYAD-01 in metastatic colorectal cancer patients

Read More

09

Nov
2019

SITC: Effect of chemotherapy on cellular kinetics of NKG2D-based CAR T-cells in metastatic colorectal cancer patients

Read More

09

Nov
2019

ICLE: The targeted knockdown of CD3ζ by shRNA as a platform to develop allogeneic CAR T cell therapy

Read More

31

Oct
2019

Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies – BioDrugs 33 (5):515-537

Read More

16

Sep
2019

ICLE: Understanding the expression profile of NKG2D ligands on T cells: Implications for CAR T cell therapy

Read More

05

Jul
2019

World Congress on Gastrointestinal Cancer: Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR T therapy in metastatic colorectal cancer

Read More

15

Jun
2019

EHA: Development of a next generation allogeneic CAR-T cell platform without gene editing

Read More

15

Jun
2019

EHA: Updated results from Phase I trials assessing a NKG2D CAR T-cell approach in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients

Read More

15

Jun
2019

EHA: Modeling NKG2D-based CAR-T cell therapy in animals with acute myeloid leukemia

Read More

18

May
2019

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma – Cancer Immunol Res 7 (1):100-112

Read More

12

Dec
2018

Overcoming Target Driven Fratricide for T Cell Therapy – Front Immunol 9:2940

Read More

03

Dec
2018

ASH: Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy Without a Prior Preconditioning Chemotherapy

Read More

03

Dec
2018

ASH: Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia

Read More

18

Nov
2018

ESMO-IO: Pooling signaling and costimulatory domains in a flexible CARpool design

Read More

18

Nov
2018

SITC: Functional screening of different anti-B7H6 CAR designs

Read More

18

Nov
2018

SITC: Differential effects of target ligands upon NKG2D CAR T cell activation

Read More

18

Nov
2018

SITC: Overcoming target‐driven fratricide for CAR‐T cell therapy

Read More

18

Nov
2018

SITC: CYAD-101: an allogeneic NKG2D CAR T cell therapy using a TCR inhibitory molecule

Read More

18

Nov
2018

SITC: Generating Allogeneic CAR T cells without Gene Editing

Read More

18

Nov
2018

SITC: Endogenous DAP10 provides optimal co‐stimulation for NKG2D‐based CARs

Read More

18

Nov
2018

SITC: Uncovering the phenotype, functional and homing properties of NKG2D CAR T cells

Read More

18

Nov
2018

SITC: The co-expression of a single shRNA targeting MICA and MICB with a NKG2D CAR generates CAR-T cells resistant to target driven fratricide and improves CAR T cell persistence in vivo

Read More

09

Nov
2018

SITC: Pooling signaling and costimulatory domains in a flexible CARpool design

Read More

09

Nov
2018

SITC: Results and perspectives from Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic solid tumors

Read More

19

Oct
2018

ESMO: Tackling fratricide to manufacture clinical grade NKG2D‐CAR T cells for cancer therapy

Read More

19

Oct
2018

ESMO: Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Metastatic Colorectal Cancer

Read More

19

Oct
2018

ESMO: The high expression of NKG2D ligands on tumor and non‐tumor cells and a lack of surface expression on healthy tissues provide a strong rationale to support NKG2D‐based therapeutic approaches for cancer.

Read More

01

Jul
2018

Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressingT cells for autologous adoptive cell therapy – Cytotherapy 20(7):952-963

Read More

19

May
2018

ASGCT: Early signs of clinical activity of NKG2D CAR-T cell (CYAD-01) activity in AML patient

Read More

16

May
2018

ASGCT: Expression of a TIM peptide reduces alloreactivity of T cells facilitating an allogeneic NKG2D Chimeric Antigen Receptor T cell therapy approach

Read More

16

May
2018

ASGCT: Overcoming target-driven fratricide for CAR-T cell therapy

Read More

16

May
2018

ASGCT: Functional screening of an anti-B7H6 specific chimeric antigen receptor (CAR)

Read More

27

Apr
2018

NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient – Haematologica 103(9):e424-e426

Read More

17

Apr
2018

AACR: The THINK clinical trial: Preliminary evidence of clinical activity of NKG2D Chimeric Antigen Receptor T cell therapy (CYAD-01) in acute myeloid leukemia

Read More

17

Apr
2018

AACR: NKG2D as a chimeric antigen receptor – DAP10 provides optimal co-stimulation for NKG2D-based CARs

Read More

17

Apr
2018

AACR: A Phase 1 study assessing the safety and clinical activity of multiple doses of an NKG2D-based CAR-T therapy, CYAD-01, administered concurrently with neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer

Read More

17

Apr
2018

AACR: A Phase 1 study assessing the safety and clinical activity of multiple hepatic transarterial administrations of an NKG2D-based CAR-T therapy, CYAD-01, in patients with unresectable liver metastases from colorectal cancer

Read More

04

Apr
2018

Celyad’s novel CAR T-cell therapy for solid malignancies – Curr Res Transl Med 66(2):53-56

Read More

14

Nov
2017

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types – BMJ Open 7(11):e017075

Read More

01

Sep
2017

ESMO: A Phase I Global Trial Targeting Multiple Solid and Hematologic Malignancies through a NKG2D receptor-based CAR-T Immunotherapy

Read More

01

Aug
2017

‘Atypical’ CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors – Immunotherapy 9(9):723-733

Read More

05

Jun
2017

ASCO: A NKG2D-based CAR-T therapy in a Multinational Phase 1 Dose Escalation and Expansion Study Targeting Multiple Solid and Hematologic Tumor Types

Read More

31

Mar
2017

Exploiting natural killer group 2D receptors for CAR T-cell therapy – Future Oncol 13(18):1593-1605

Read More

27

Mar
2017

Whitepaper – CAR T NKR-2: Leveraging the Breadth of Innate Immunity

Read More

06

Dec
2016

CAR-TCR: Safety Data from a First-in-Human Phase I Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma

Read More

13

Sep
2016

ASH: Safety Data from a First-in-Human Phase I Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma

Read More

04

Jun
2016

ASCO: A First-in-Human Phase I Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma

Read More
Learn About Celyad Oncology's Pipeline

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use